Home › Compare › NEOJF vs ABBV
NEOJF yields 2.73% · ABBV yields 3.06%● Live data
📍 NEOJF pulled ahead of the other in Year 3
Combined, NEOJF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NEOJF + ABBV for your $10,000?
NEOJAPAN Inc. engages in development and sale of packaged software to small and medium-sized enterprises, large companies, schools, hospitals, local governments, and public agencies in Japan and internationally. The company offers desknet's NEO, a groupware software; AppSuite, a tool to create custom business applications; and ChatLuck, a chat-based business communication tool. It also provides Denbun, a web-based email system for corporate clients that manages, sends, and receives emails through a web browser; desknet's DAX, a file transfer system; desknet's SSS, a web-based sales management system, which enables to monitor progress in business negotiations, client info, and sales; and desknet's CAMS, a web-based customer relationship management system. In addition, it provides multi-application integration and hosting services; and system integration services, such as e-business system, e-commerce website, infrastructure and middleware, application service provider website construction, and online information distribution services. The company was incorporated in 1992 and is headquartered in Yokohama, Japan.
Full NEOJF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.